Vital expertise in virotherapy manufacturing
Specializing in live viruses and viral vectors─ we enable our customers in the development and manufacture of transformational oncolytic virus, gene therapy, and vaccine products to advance human health.
Since 2002, we have supported global clientele across clinical and regulatory arenas with comprehensive CDMO services
ABOUT US: High quality, efficiency, and scientific expertise define our service.Learn more
FACILITIES: US and EU locations provide flexibility and security of supply.Explore our facilities
From starting material generation to full drug substance and product capabilities
Vibalogics can assist you through a comprehensive service portfolio – ensuring the success of your virotherapy, beginning with process development and technical transfer feasibility, through cGMP production and validation.
Cell & Virus Banking
High-quality master and working cell and virus seed banking services provide critical starting materials for clinical-and-commercial supply.
Drug Substance & Drug Product
Single-use production technologies, adherent and suspension processes, and non-aseptic or aseptic conditions from 50-2000L scale.
Liquid and lyophilized fill for up to 40,000k vial batches is offered in high-throughput fill lines by Bosch and Bausch+Ströbel.
Full development services are offered to transfer and mature processes for optimized scale, productivity, product profile and cost of goods.
Method development and transfer services span characterization and quality control assays for identity, purity, potency, titer, and safety.
QC Release & Stability Testing
In-house quality control and stability services ensure timely testing of bulk, in-process control, and final drug product.
Specialist in the manufacture of replication competent engineered and wild-type oncolytic viruses, with a deep track record you can trust.
Expertise across gene therapy vectors produced by transient, helper-virus, and stable producer cell lines minimize time-to-market.
Scalable capacity and effective cost of goods management for vaccine product development and manufacture.
What makes us the best choice
A “Pure-Play” Virotherapy CDMO
20 years focused on delivering virotherapy services with over $200M in active investment.
Critical guidance and technical oversight enable our customers development of robust products and processes for clinical- and commercial-use.
Complete offerings from GMP cell & viral banking, process and analytical development, GMP drug substance and drug product fill & finish.
Capacity & Quality
BSL-2 facilities and continues reinvestment provide capacity-rich infrastructure with quality compliance to international GMP standards.
GMP Manufacturing of Oncolytic Viruses: Critical Steps and Key Considerations
In our latest edition of Virotherapy Insider: Deep Dive, we will discuss the critical steps involved in OV development, manufacturing, testing, and explore the measures that need to be taken at each stage to ensure success.